Oculis price target raised to $51 from $33 at Chardan

Chardan raised the firm’s price target on Oculis (OCS) to $51 from $33 and keeps a Buy rating on the shares. Oculis announced that privosegtor will advance into two registrational studies for acute optic neuritis and one for non-arteritic anterior ischemic optic neuritis, accelerating timelines relative to prior guidance, the analyst tells investors in a research note. The update reflects the company’s growing confidence in the asset following strong Phase 2 ACUITY AON results earlier this year.